$MDCX News

Medicus Pharma Outlines Clinical Development Strategy Across Three Drug Programs Following $90 Million in Financing

Medicus Pharma (MDCX) Shares Fall 24% After Hours: Here's Why

Medicus Pharma Announces 50-For-1 Stock Split, Effective Oct. 12

Medicus Pharma seeks FDA alignment on streamlined Phase 2b/3 Teverelix study

Medicus Pharma files streamlined Phase 2b/3 prostate cancer trial design with FDA

Medicus Pharma Submits Optimized Teverelix® Registrational Protocol to FDA to Create Partner Ready Program in Advanced Prostate Cancer

Medicus Pharma Files Optimized Seamless Phase 2b/3 Registration-Intent Protocol To FDA For Teverelix To Treat Advanced Prostate Cancer

Medicus Pharma to focus SkinJect development exclusively on Gorlin syndrome patients

Medicus Pharma Optimizes Portfolio Strategy With High-Value Focus

Medicus Pharma Announces Exclusive Development Focus for SkinJect® in Gorlin Syndrome Following Commercial, Clinical and Regulatory Assessment

Medicus Pharma Optimizes Portfolio Strategy With High-Value Focus

Medicus Pharma And Yorkville Mutually Agree To Terminate Standby Equity Purchase Agreement For Up To $15M Of Stock

Medicus Pharma CEO on SkinJect and Pfizer partnership – ICYMI

Medicus Pharma Identifies 200 µg SkinJect Patch as Lead Development Dose After Phase 2 Study

Medicus Pharma reports positive Phase 2 data for SkinJect in skin cancer treatment

Medicus Pharma Publishes Abridged Final Phase 2 SkinJect® Clinical Study Report (CSR) Results Identifying 200 µg D-MNA Patch as the Lead Development Dose

Medicus Pharma Posts Phase 2 Clinical Study Report For SKNJCT‑003 On ClinicalTrials.gov, Offering Public Access To Efficacy, Safety, And Drug‑Delivery Findings

Medicus Pharma reorients around new cancer drug candidate, sharpens focus for other programs

Medicus Pharma Prioritises CD228V Oncology Programme in Development Strategy

Medicus Pharma Advances Transformation into a Precision Oncology-Led Biotechnology Company